Cartesian Therapeutics Announces New Employment Inducement Grants

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to two new employees. The company issued stock options to purchase 5,750 shares at an exercise price of $12.48 per share on August 4, 2025.

The options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan with a four-year vesting schedule. The initial 25% vests on August 4, 2026, followed by three equal annual installments, becoming fully vested by August 4, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4).

FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On August 4, 2025, the Company issued to these employees options to purchase an aggregate of 5,750 shares of the Company’s common stock with an exercise price of $12.48, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on August 4, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on August 4, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

What stock options did Cartesian Therapeutics (RNAC) grant to new employees in August 2025?

Cartesian Therapeutics granted options to purchase 5,750 shares at an exercise price of $12.48 per share to two new employees.

What is the vesting schedule for RNAC's August 2025 employee stock options?

The options vest 25% on August 4, 2026, followed by three equal annual installments, becoming fully vested on August 4, 2029.

Under what plan were Cartesian Therapeutics' employee stock options granted?

The options were granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and Nasdaq Rule 5635(c)(4).

When do the RNAC employee stock options expire?

The stock options have a ten-year term, expiring in August 2035.